Are CJC-1295 and ipamorelin a safe, natural way to boost growth hormone?

What these peptides are

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). The version tested in published human studies binds to albumin in the blood after injection, which gives it a half-life of about 8 days. Online sellers also use the name CJC-1295 for a version without this albumin-binding feature, often called modified GRF(1-29) or CJC-1295 without DAC. A 2026 endocrinology review treats these as separate agents, and the published human trials do not describe the version without DAC.

Ipamorelin is a synthetic five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts on the ghrelin/growth hormone secretagogue receptor. Its 1998 development paper showed that in pigs it released growth hormone without raising ACTH or cortisol, unlike older peptides of the same class. That animal finding is the source of its reputation as a selective or gentle option.

Sources: PubMed 17018654 · PubMed 42395176 · PubMed 9849822

The part that is supported: they raise growth hormone

In two randomized, placebo-controlled, double-blind trials in healthy adults aged 21-61 (lasting 28 and 49 days), a single injection of CJC-1295 raised mean growth hormone 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9-11 days. With repeated doses, IGF-I stayed above baseline for up to 28 days. No serious adverse reactions were reported in those trials. A separate study in healthy men aged 20-40 found that growth hormone pulses persisted, while trough levels rose 7.5-fold, mean growth hormone by 46% and IGF-I by 45%.

For ipamorelin, a 1999 dose-escalation study in healthy men (eight per dose level, five levels) found that each infusion produced a single burst of growth hormone, peaking at about 0.67 hours, and that the drug had a terminal half-life of about 2 hours. So the hormone-raising part of the claim is backed by human data.

Sources: PubMed 16352683 · PubMed 17018654 · PubMed 10496658

What has not been shown

Raising a hormone level is a lab result, not a health benefit. In our PubMed searches we found no published trial of CJC-1295 and ipamorelin used together. A 2026 orthopaedic primer notes that the only muscle findings for the combination come from mice. A 2026 scoping review in The American Journal of Sports Medicine concluded that claims of better recovery and performance from these peptides are not backed by current human trials.

When ipamorelin was tested against a real clinical endpoint, it did not beat placebo. In a Phase 2 randomized trial in 114 patients after bowel surgery, median time to the first tolerated solid meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, a difference that was not statistically significant (p = 0.15).

Sources: PubMed 41476424 · PubMed 42578445 · PubMed 25331030

Why "safe" is not established

The FDA states that it has identified serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and that clinical data are limited. For ipamorelin, which is in category 2 for 503B outsourcing facilities, the FDA cites a published study in which serious adverse events, including death, were identified when ipamorelin was given intravenously for gastric motility. It also flags possible immune reactions and the complexity of characterizing peptides that contain unnatural amino acids.

Reviews of people using these peptides on their own describe raised prolactin and cortisol, appetite changes, blood sugar problems, fluid retention, muscle and joint pain and injection-site reactions. They also describe a biologically plausible but unproven concern about stimulating cell growth. Products from unregulated supply chains may be mislabeled or contaminated, and a 2018 analysis of black-market products found modified versions of growth hormone-releasing peptides, including a glycine-extended ipamorelin. The controlled human trials lasted weeks, so long-term safety is unknown.

Sources: fda.gov · PubMed 42395176 · PubMed 41880199 · PubMed 29864719

Why "natural" is misleading, and the regulatory picture

Both peptides act on the body's own growth hormone system, but neither is a natural hormone. CJC-1295 was engineered to bind albumin and keep stimulating the pituitary for days, which is very different from the body's short, pulsed GHRH signals. Ipamorelin contains non-standard and D-form amino acids that do not occur in human proteins. Saying a drug works through a natural pathway does not make the drug itself natural or safe.

Neither peptide has regulatory approval for physique- or performance-related uses, according to a 2026 endocrinology review. Growth hormone releasing factors, including GHRH analogues and growth hormone secretagogues, are prohibited at all times under the WADA Prohibited List. A 2026 sports-medicine review concluded that growth hormone axis secretagogues such as CJC-1295 and ipamorelin remain investigational, with uncertain safety and product-quality concerns.

Sources: PubMed 17018654 · PubMed 9849822 · PubMed 42395176 · PubMed 42160466 · wada-ama.org

Profiles

CJC-1295 profile → · Ipamorelin profile → · Modified GRF 1-29 profile →

References

1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab · 2006 · PMID 16352683
2. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab · 2006 · PMID 17018654
3. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res · 1999 · PMID 10496658
4. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol · 1998 · PMID 9849822
5. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne) · 2026 · PMID 42395176
6. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med · 2026 · PMID 41476424
7. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med · 2026 · PMID 42578445
8. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis · 2014 · PMID 25331030
9. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. J Sports Med Phys Fitness · 2026 · PMID 41880199
10. Analysis of new growth promoting black market products. Growth Horm IGF Res · 2018 · PMID 29864719
11. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS Rev · 2026 · PMID 42160466

Other sources

• https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
• https://www.wada-ama.org/en/prohibited-list

These are original summaries of published research, written with AI assistance and checked against the cited sources. They are not medical advice and have not been reviewed by a clinician. Every PubMed reference was checked against PubMed's record for title, year and journal. All claim checks · Editorial standards